Philip J Peyton, Sabine Braat, Anurika De Silva, David Story, Lisbeth Evered, Paul S Myles, Matthew Chan, Stephan Schug, Malcolm Hogg, Alex Holmes, Sofia Sidiropoulos, Kate Leslie
{"title":"Rationale and design of a large trial of perioperative ketamine for prevention of chronic post-surgical pain.","authors":"Philip J Peyton, Sabine Braat, Anurika De Silva, David Story, Lisbeth Evered, Paul S Myles, Matthew Chan, Stephan Schug, Malcolm Hogg, Alex Holmes, Sofia Sidiropoulos, Kate Leslie","doi":"10.1186/s13063-024-08672-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic post-surgical pain (CPSP) is recognised as one of the most common and debilitating complications of major surgery. Progression from acute to chronic pain after surgery involves sensitisation of central nervous system pathways with the N-methyl-D-aspartate (NMDA) receptor having a central role. Ketamine is a potent, non-selective NMDA antagonist commonly used for management of acute postoperative pain. Inconsistent but largely supportive evidence from small trials of a preventative effect of perioperative ketamine on CPSP risk suggests that a confirmative large trial is needed.</p><p><strong>Methods: </strong>The ROCKet (Reduction Of Chronic Post-surgical Pain with Ketamine) Trial is a multicentre, double-blind, placebo-controlled, individually randomised superiority trial conducted in 36 hospitals across Australia, New Zealand, and Hong Kong. The trial aims to recruit 4884 patients undergoing abdominal, thoracic, or major orthopaedic surgery. Eligible participants are randomised equally to perioperative intravenous ketamine or placebo for up to 72 h. Incidence of pain in the area of the index surgery is measured by structured telephone interview at 3 months (primary trial endpoint) and 12 months. Pain severity, nature, and associated psychological and quality of life indices are measured using the modified Brief Pain Inventory short form, Neuropathic Pain Questionnaire, Kessler K-10 Psychological Distress Scale, Pain Catastrophising Scale, EQ-5D-3L, and measures of healthcare utilisation and costs. The trial is being conducted by the Department of Critical Care, University of Melbourne, and the Australian and New Zealand College of Anaesthetists Clinical Trials Network. The trial is funded by the Australian National Health and Medical Research Council.</p><p><strong>Discussion: </strong>The ROCKet trial will clarify the effectiveness of ketamine in primary prevention of CPSP. In addition, it will provide high-quality, prospective data on the epidemiology of CPSP which will better inform further research into prevention and management of CPSP.</p><p><strong>Trial registration: </strong>Australian New Zealand Clinical Trials Registry (ACTRN12617001619336) on the date of 12/11/2017.</p>","PeriodicalId":23333,"journal":{"name":"Trials","volume":"25 1","pages":"840"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660817/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13063-024-08672-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chronic post-surgical pain (CPSP) is recognised as one of the most common and debilitating complications of major surgery. Progression from acute to chronic pain after surgery involves sensitisation of central nervous system pathways with the N-methyl-D-aspartate (NMDA) receptor having a central role. Ketamine is a potent, non-selective NMDA antagonist commonly used for management of acute postoperative pain. Inconsistent but largely supportive evidence from small trials of a preventative effect of perioperative ketamine on CPSP risk suggests that a confirmative large trial is needed.
Methods: The ROCKet (Reduction Of Chronic Post-surgical Pain with Ketamine) Trial is a multicentre, double-blind, placebo-controlled, individually randomised superiority trial conducted in 36 hospitals across Australia, New Zealand, and Hong Kong. The trial aims to recruit 4884 patients undergoing abdominal, thoracic, or major orthopaedic surgery. Eligible participants are randomised equally to perioperative intravenous ketamine or placebo for up to 72 h. Incidence of pain in the area of the index surgery is measured by structured telephone interview at 3 months (primary trial endpoint) and 12 months. Pain severity, nature, and associated psychological and quality of life indices are measured using the modified Brief Pain Inventory short form, Neuropathic Pain Questionnaire, Kessler K-10 Psychological Distress Scale, Pain Catastrophising Scale, EQ-5D-3L, and measures of healthcare utilisation and costs. The trial is being conducted by the Department of Critical Care, University of Melbourne, and the Australian and New Zealand College of Anaesthetists Clinical Trials Network. The trial is funded by the Australian National Health and Medical Research Council.
Discussion: The ROCKet trial will clarify the effectiveness of ketamine in primary prevention of CPSP. In addition, it will provide high-quality, prospective data on the epidemiology of CPSP which will better inform further research into prevention and management of CPSP.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12617001619336) on the date of 12/11/2017.
背景:慢性术后疼痛(CPSP)被认为是大手术最常见和最令人衰弱的并发症之一。手术后从急性疼痛到慢性疼痛的进展涉及中枢神经系统通路的致敏,其中n -甲基- d -天冬氨酸(NMDA)受体起核心作用。氯胺酮是一种有效的非选择性NMDA拮抗剂,通常用于治疗急性术后疼痛。围手术期氯胺酮对CPSP风险的预防作用的小型试验证据不一致,但在很大程度上是支持性的,这表明需要进行确认性的大型试验。ROCKet(氯胺酮减轻术后慢性疼痛)试验是一项多中心、双盲、安慰剂对照、单独随机的优势试验,在澳大利亚、新西兰和香港的36家医院进行。该试验旨在招募4884名接受腹部、胸部或主要骨科手术的患者。符合条件的参与者被随机随机分配到围手术期静脉注射氯胺酮或安慰剂组长达72小时。在3个月(主要试验终点)和12个月时,通过结构化电话访谈测量食指手术区域的疼痛发生率。疼痛的严重程度、性质以及相关的心理和生活质量指标采用修改后的简短疼痛量表、神经性疼痛问卷、Kessler K-10心理困扰量表、疼痛灾难量表、EQ-5D-3L以及医疗保健利用和成本的测量来测量。该试验由墨尔本大学重症监护部和澳大利亚和新西兰麻醉师学院临床试验网络进行。该试验由澳大利亚国家健康和医学研究委员会资助。讨论:ROCKet试验将阐明氯胺酮在CPSP一级预防中的有效性。此外,它将为CPSP的流行病学提供高质量的前瞻性数据,为CPSP的预防和管理研究提供更好的信息。试验注册:澳大利亚新西兰临床试验注册中心(ACTRN12617001619336),注册日期为2017年12月11日。
期刊介绍:
Trials is an open access, peer-reviewed, online journal that will encompass all aspects of the performance and findings of randomized controlled trials. Trials will experiment with, and then refine, innovative approaches to improving communication about trials. We are keen to move beyond publishing traditional trial results articles (although these will be included). We believe this represents an exciting opportunity to advance the science and reporting of trials. Prior to 2006, Trials was published as Current Controlled Trials in Cardiovascular Medicine (CCTCVM). All published CCTCVM articles are available via the Trials website and citations to CCTCVM article URLs will continue to be supported.